Pre-surgery chemotherapy and immunotherapy for operable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have confirmed pancreatic adenocarcinoma that doctors think can be removed with surgery.
- Your scans (CT/MRI) must show the cancer has not spread to distant organs and has the right blood-vessel involvement to still be potentially resectable.
- You have not had chemotherapy or radiation for pancreatic cancer before.
- Your general health is fairly strong (ECOG performance status 0–1) and you can follow all study steps.
- Your blood counts and organ function (kidneys, liver, blood clotting) meet required lab thresholds before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (durvalumab and oleclumab) given before surgery to people with pancreatic cancer that can be removed. The goal is to see if this treatment helps the immune system fight the cancer better.
This trial tests a combination of chemotherapy, radiation, and immunotherapy (pembrolizumab) before surgery for pancreatic cancer that can be removed. It aims to see if this triple therapy helps shrink tumors and improve survival.
This trial tests a combination of chemotherapy drugs (mFOLFIRINOX) given before surgery to people with pancreatic cancer that may be removable. The goal is to see if this approach works well and to prepare for a larger study.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests whether giving treatment before surgery helps people with pancreatic cancer that can be removed. The treatment is given before the operation, and the study checks if it is safe and effective.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.